• +1-646-491-9876
    • +91-20-67278686

    Search

    Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) - Pipeline Review, H2 2016

    Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) - Pipeline Review, H2 2016

    • Report Code ID: RW0001513514
    • Category Pharmaceuticals
    • No. of Pages 70
    • Publication Month Nov-16
    • Publisher Name Global Markets Direct
    Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) - Pipeline Review, H2 2016

    Summary

    Publisher's, 'Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) - Pipeline Review, H2 2016', provides in depth analysis on Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) targeted pipeline therapeutics.

    The report provides comprehensive information on the Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) targeted therapeutics development and features dormant and discontinued projects.

    Publisher's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

    The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

    Note:
    *Certain sections in the report may be removed or altered based on the availability and relevance of data.
    *Updated report will be delivered in 48 hours of order confirmation.

    Scope

    - The report provides a snapshot of the global therapeutic landscape for Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3)
    - The report reviews Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
    - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
    - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
    - The report reviews key players involved in Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) targeted therapeutics and enlists all their major and minor projects
    - The report assesses Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
    - The report summarizes all the dormant and discontinued pipeline projects
    - The report reviews latest news and deals related to Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) targeted therapeutics

    Reasons to buy

    - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
    - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
    - Identify and understand the targeted therapy areas and indications for Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3)
    - Identify the use of drugs for target identification and drug repurposing
    - Identify potential new clients or partners in the target demographic
    - Develop strategic initiatives by understanding the focus areas of leading companies
    - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
    - Devise corrective measures for pipeline projects by understanding Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) development landscape
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
    Table of Contents

    List of Tables 5
    List of Figures 5
    Introduction 6
    Publisher Report Coverage 6
    Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) Overview 7
    Therapeutics Development 8
    Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) - Products under Development by Stage of Development 8
    Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) - Products under Development by Therapy Area 9
    Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) - Products under Development by Indication 10
    Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) - Pipeline Products Glance 12
    Late Stage Products 12
    Early Stage Products 13
    Unknown Stage Products 14
    Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) - Products under Development by Companies 15
    Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) - Products under Development by Universities/Institutes 17
    Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) - Therapeutics Assessment 19
    Assessment by Monotherapy/Combination Products 19
    Assessment by Mechanism of Action 20
    Assessment by Route of Administration 22
    Assessment by Molecule Type 24
    Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) - Companies Involved in Therapeutics Development 26
    Merck & Co Inc 26
    SciFluor Life Sciences LLC 27
    SOM Biotech SL 28
    Tissue Therapies Ltd 29
    TWi Pharmaceuticals Inc 30
    Vascular Pharmaceuticals Inc 31
    Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) - Drug Profiles 32
    A-11 - Drug Profile 32
    Product Description 32
    Mechanism Of Action 32
    R&D Progress 32
    AC-301 - Drug Profile 33
    Product Description 33
    Mechanism Of Action 33
    R&D Progress 33
    C-16Y - Drug Profile 34
    Product Description 34
    Mechanism Of Action 34
    R&D Progress 34
    cilengitide - Drug Profile 35
    Product Description 35
    Mechanism Of Action 35
    R&D Progress 35
    MK-0429 - Drug Profile 37
    Product Description 37
    Mechanism Of Action 37
    R&D Progress 37
    OCU-200 - Drug Profile 38
    Product Description 38
    Mechanism Of Action 38
    R&D Progress 38
    Peptides to Antagonize Alpha-V Beta-3 Integrin Receptor for Melanoma - Drug Profile 39
    Product Description 39
    Mechanism Of Action 39
    R&D Progress 39
    Proagio - Drug Profile 40
    Product Description 40
    Mechanism Of Action 40
    R&D Progress 40
    Protein to Agonize Integrin Alpha V, Beta 3 and Beta 5 for Malabsorption Syndrome - Drug Profile 41
    Product Description 41
    Mechanism Of Action 41
    R&D Progress 41
    Recombinant Protein to Antagonize ITGA2B and ITGB3 for Arterial Thrombosis and Ischemic Cerebral Stroke - Drug Profile 42
    Product Description 42
    Mechanism Of Action 42
    R&D Progress 42
    RSF-201 - Drug Profile 43
    Product Description 43
    Mechanism Of Action 43
    R&D Progress 43
    RUC-4 - Drug Profile 44
    Product Description 44
    Mechanism Of Action 44
    R&D Progress 44
    SF-0166 - Drug Profile 45
    Product Description 45
    Mechanism Of Action 45
    R&D Progress 45
    SOM-0777 - Drug Profile 46
    Product Description 46
    Mechanism Of Action 46
    R&D Progress 46
    tetraiodothyroacetic acid - Drug Profile 47
    Product Description 47
    Mechanism Of Action 47
    R&D Progress 47
    VF-001 - Drug Profile 48
    Product Description 48
    Mechanism Of Action 48
    R&D Progress 48
    VPI-2690B - Drug Profile 49
    Product Description 49
    Mechanism Of Action 49
    R&D Progress 49
    Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) - Dormant Projects 50
    Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) - Discontinued Products 55
    Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) - Featured News & Press Releases 56
    Nov 07, 2016: FDA Clinical Hold Lifted for IND 119526 (VF - 001) 56
    Oct 17, 2016: SciFluor Life Sciences Announces First Patients Dosed in Retinal Program with Investigational New Drug Application for SF0166 Topical Ophthalmic Solution 56
    Oct 10, 2016: Submission of IND Amendments for Phase II Study of VF - 001 in the US 57
    Aug 03, 2016: Factor Therapeutics Announces Formation of Medical Advisory Board 57
    Aug 01, 2016: SciFluor Life Sciences Enters Clinical Trial Stage for Novel Treatment for Retinal Diseases 59
    May 31, 2016: New Class of Protein Could Treat Cancer and Other Diseases, Georgia State Researchers Find 60
    May 25, 2016: Iceni Pharmaceuticals launches as new company focusing on repurposing therapies in the field of oncology 61
    Mar 09, 2016: SciFluor Life Sciences Awarded Second U.S. Patent for Integrin avß3 (SF0166) Inhibitors Designed for the Topical Treatment of Retinal Disease 61
    Feb 11, 2016: Ocugen Announces Patent Allowance For Ocu-200 62
    Dec 17, 2015: Tissue Therapies Provides FDA Regulatory Progress Update 63
    Feb 25, 2013: Merck Serono Announces Phase III Trial Of Cilengitide Did Not Meet Primary Endpoint In Patients With Newly Diagnosed Glioblastoma 64
    Jun 09, 2011: Merck Serono Completes Patient Enrollment For Cilengitide's Pivotal Phase III Trial CENTRIC 65
    Jun 05, 2010: EMD Serono Announces Long-Term Follow-up Data From Cilengitide Study In Glioblastoma Patients 66
    May 31, 2009: Study Shows Cilengitide Increased Overall Survival In Patients With Glioblastoma 67
    Mar 16, 2009: Merck Serono Expands Cilengitide Development Program 67
    Appendix 69
    Methodology 69
    Coverage 69
    Secondary Research 69
    Primary Research 69
    Expert Panel Validation 69
    Contact Us 69
    Disclaimer 70

    List of Tables

    Number of Products under Development for, H2 2016 8
    Number of Products under Development by Therapy Area, H2 2016 9
    Number of Products under Development by Indication, H2 2016 11
    Comparative Analysis by Late Stage Development, H2 2016 12
    Comparative Analysis by Early Stage Products, H2 2016 13
    Comparative Analysis by Unknown Stage Development, H2 2016 14
    Number of Products under Development by Companies, H2 2016 15
    Products under Development by Companies, H2 2016 16
    Number of Products under Investigation by Universities/Institutes, H2 2016 17
    Products under Investigation by Universities/Institutes, H2 2016 18
    Assessment by Monotherapy/Combination Products, H2 2016 19
    Number of Products by Stage and Mechanism of Action, H2 2016 21
    Number of Products by Stage and Route of Administration, H2 2016 23
    Number of Products by Stage and Molecule Type, H2 2016 25
    Pipeline by Merck & Co Inc, H2 2016 26
    Pipeline by SciFluor Life Sciences LLC, H2 2016 27
    Pipeline by SOM Biotech SL, H2 2016 28
    Pipeline by Tissue Therapies Ltd, H2 2016 29
    Pipeline by TWi Pharmaceuticals Inc, H2 2016 30
    Pipeline by Vascular Pharmaceuticals Inc, H2 2016 31
    Dormant Projects, H2 2016 50
    Dormant Projects (Contd..1), H2 2016 51
    Dormant Projects (Contd..2), H2 2016 52
    Dormant Projects (Contd..3), H2 2016 53
    Dormant Projects (Contd..4), H2 2016 54
    Discontinued Products, H2 2016 55

    List of Figures

    Number of Products under Development for, H2 2016 8
    Number of Products under Development by Therapy Area, H2 2016 9
    Number of Products under Development by Top 10 Indication, H2 2016 10
    Comparative Analysis by Early Stage Products, H2 2016 13
    Assessment by Monotherapy/Combination Products, H2 2016 19
    Number of Products by Mechanism of Actions, H2 2016 20
    Number of Products by Stage and Mechanism of Actions, H2 2016 20
    Number of Products by Routes of Administration, H2 2016 22
    Number of Products by Stage and Routes of Administration, H2 2016 22
    Number of Products by Molecule Types, H2 2016 24
    Number of Products by Stage and Molecule Type, H2 2016 24
    Merck & Co Inc
    SciFluor Life Sciences LLC
    SOM Biotech SL
    Tissue Therapies Ltd
    TWi Pharmaceuticals Inc
    Vascular Pharmaceuticals Inc

    Request for Sample

    Report Url https://www.reportsweb.com//integrin-beta-3-pipeline-review-h2-2016&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url https://www.reportsweb.com//integrin-beta-3-pipeline-review-h2-2016&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url https://www.reportsweb.com//integrin-beta-3-pipeline-review-h2-2016&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments